Literature DB >> 1421437

Influence of O6-methylguanine on DNA damage and cytotoxicity of temozolomide in L1210 mouse leukemia sensitive and resistant to chloroethylnitrosoureas.

P Taverna1, C V Catapano, L Citti, M Bonfanti, M D'Incalci.   

Abstract

Temozolomide is a new anticancer agent which in the early clinical investigation has shown promising antitumor activity. It decomposes spontaneously to the active metabolite of DTIC (MTIC). Temozolomide is more cytotoxic against L1210 than against a subline L1210/BCNU, resistant to chloroethylnitrosoureas. Using [methyl-3H] temozolomide we found that after 1 h exposure the amount of O6-methylguanine (O6mGua) was twice as high in L1210 than in L1210/BCNU whereas the amount of N7 mGua was approximately the same in the two cell lines. O6-alkylguanine DNA alkyltransferase (AT) levels were higher in L1210/BCNU than in L1210, supporting the view that the resistance to methyltriazenes is probably related to the efficient repair of O6mGua in L1210/BCNU. Exposure of L1210/BCNU cells to 0.4 mM O6mGua for 24 h resulted in a depletion of AT and in a higher temozolomide-induced cytotoxicity. In the sensitive cell line L1210, temozolomide activity was not potentiated by O6mGua pretreatment. Moreover, in L1210/BCNU, O6mGua increased DNA single-strand breaks caused by temozolomide, suggesting that O6-guanine alkylation induces an excision repair mechanism in cells depleted in AT.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1421437     DOI: 10.1097/00001813-199208000-00014

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  4 in total

1.  Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study.

Authors:  Terzah M Horton; Patrick A Thompson; Stacey L Berg; Peter C Adamson; Ashish M Ingle; M Eileen Dolan; Shannon M Delaney; Madhuri Hedge; Heidi L Weiss; Meng-Fen Wu; Susan M Blaney
Journal:  J Clin Oncol       Date:  2007-11-01       Impact factor: 44.544

2.  Multiscale design of cell-type-specific pharmacokinetic/pharmacodynamic models for personalized medicine: application to temozolomide in brain tumors.

Authors:  A Ballesta; Q Zhou; X Zhang; H Lv; J M Gallo
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-04-30

3.  Temozolomide and cisplatin in relapsed/refractory acute leukemia.

Authors:  Karen Seiter; Sreedhar Katragadda; Doris Ponce; Muhammad Rasul; Nasir Ahmed
Journal:  J Hematol Oncol       Date:  2009-05-22       Impact factor: 17.388

4.  Transcription elongation past O6-methylguanine by human RNA polymerase II and bacteriophage T7 RNA polymerase.

Authors:  Alexandra Dimitri; John A Burns; Suse Broyde; David A Scicchitano
Journal:  Nucleic Acids Res       Date:  2008-10-14       Impact factor: 16.971

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.